The following statements about denosumab are correct, except?
Denosumab inhibits the development and activation of osteoclasts
Bone resorption markers decrease rapidly after initiation of denosumab treatment
Its antiresorptive effects are irreversible upon discontinuation of treatment
Denosumab binds RANKL
Denosumab has a faster onset of action than alendronate
Discontinuation of denosumab treatments results in an increase in bone turnover markers
Bisphosphonates are recommended after denosumab discontinuation
Discontinuation of denosumab treatment leads to an increased risk of vertebral fracture
Denosumab is a fully human monoclonal antibody
Denosumab can be taken orally
When denosumab is discontinued
It is recommended to switch to teriparatide to maximise bone gain
It is recommended to switch to alendronate or zoledronic acid to avoid rebound effect and vertebral fractures
Antiresorptive treatments should be initiated 1 year after the last denosumab injection
It is not necessary to propose any other treatment
There is no need to monitor patients closely, particularly during the first 12 months
What is denosumab's main mechanism of action?
Binds to bone mineral to inhibit osteoclast activity
Inhibits RANKL to inhibit osteoclast formation
Suppresses osteoblast activity
Stimulates collagen production in bone
Inhibits osteocyte activity
Which type of fracture is significantly reduced by denosumab?
Vertebral fractures
Non-vertebral fractures
Hip fractures
All of the above